Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
136.01
-0.64 (-0.47%)
Feb 21, 2025, 4:00 PM EST - Market closed
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Jazz Pharmaceuticals stock have an average target of 177.5, with a low estimate of 113 and a high estimate of 230. The average target predicts an increase of 30.51% from the current stock price of 136.01.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Hold | 4 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $130 → $170 | Hold → Buy | Upgrades | $130 → $170 | +24.99% | Feb 13, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $163 | Buy | Reiterates | $163 | +19.84% | Dec 12, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $179 | Buy | Reiterates | $179 | +31.61% | Dec 12, 2024 |
| Needham | Needham | Strong Buy Reiterates $207 | Strong Buy | Reiterates | $207 | +52.19% | Dec 12, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $179 | Buy | Reiterates | $179 | +31.61% | Dec 10, 2024 |
Financial Forecast
Revenue This Year
4.12B
from 3.83B
Increased by 7.53%
Revenue Next Year
4.41B
from 4.12B
Increased by 6.94%
EPS This Year
20.80
from 6.10
Increased by 240.83%
EPS Next Year
22.35
from 20.80
Increased by 7.49%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.3B | 4.8B | 5.1B | |||
| Avg | 4.1B | 4.4B | 4.6B | |||
| Low | 3.9B | 3.9B | 4.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 11.7% | 15.6% | 15.8% | |||
| Avg | 7.5% | 6.9% | 4.4% | |||
| Low | 2.4% | -5.0% | -10.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 21.84 | 26.73 | 26.41 | |||
| Avg | 20.80 | 22.35 | 22.92 | |||
| Low | 19.66 | 18.17 | 17.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 257.9% | 28.6% | 18.1% | |||
| Avg | 240.8% | 7.5% | 2.6% | |||
| Low | 222.2% | -12.6% | -23.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.